We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ADHD drug

News List

Supernus says ADHD drug trounces rivals, but shares slide pharmaphorum
December 10, 2018
Supernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, but still saw its shares fall as investors digested the data.
Shire launches new ADHD drug Mydayis as it weighs a neuroscience exit fiercepharma
August 29, 2017
Shire announced a copay offer with its full U.S. launch of Mydayis, a reformulation of its well-known Adderall.
Shire long-acting ADHD drug finally approved pharmaphorum
June 22, 2017
Shire’s long-acting attention deficit drug has been approved in the US after languishing in regulatory purgatory for more than a decade.
Glenmark gets US FDA nod for ADHD drug financialexpress
June 01, 2017
According to IMS Health sales data for the 12 months to April 2017, Strattera capsules achieved annual sales of approximately $1.1 billion
Shire refiles ADHD drug pharmatimes
January 22, 2017
Shire has refiled its experimental attention deficit hyperactivity disorder drug SHP 465 in the US, having garnered new data further backing its safety and efficacy.